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Résumé en
anglais
CONTEXT: Untreated acromegaly is associated with increased morbidity and
mortality due to malignant, cardiovascular, and cerebrovascular disorders. Effective
treatment of acromegaly reduces excess mortality, but its impact on cardiovascular
risk factors and metabolic parameters are poorly documented.
AIM: We analyzed changes in cardiovascular risk factors and metabolic parameters
in patients receiving various treatment modalities.
PATIENTS AND METHODS: We retrospectively studied 96 patients with acromegaly,
both at diagnosis and after IGF-I normalization following surgery alone (n = 51) or
medical therapy with first generation somatostatin analogues (SSA, n = 23), or
pegvisomant (n = 22). Duration of follow-up was 77 (42-161) months, 75 (42-112)
months, and 62 (31-93) months, in patients treated with surgery alone, SSA, and
pegvisomant, respectively. In all the cases except four, patients treated medically
had underwent previous unsuccessful surgery.
RESULTS: IGF-I normalization was associated with increased body weight,
decreased systolic blood pressure (SBP) in hypertensive patients, decreased fasting
plasma glucose (FPG) and HOMA-IR and HOMA-B levels, increased HDL cholesterol
(HDLc); whereas, LDL cholesterol (LDLc) was not significantly different. Plasma
PCSK9 levels were unchanged in patients with available values. Cardiovascular and
metabolic changes varied with the treatment modality: surgery, but not pegvisomant,
had a beneficial effect on SBP; FPG decreased after surgery but increased after SSA;
the decline in HOMA-IR was only significant after surgery; pegvisomant significantly
increased LDLc and total cholesterol; whereas SA increased HDLc and had no effect
on LDLc levels.
CONCLUSION: Treatments used to normalize IGF-I levels in patients with
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